Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Ayala Pharmaceuticals and Biosight Enter into Merger Agreement

Friday, July 28, 2023

Ayala Pharmaceuticals announced they have entered into a definitive merger agreement forming a new combined company that will operate under the name Ayala Pharmaceuticals.

According to the merger agreement, Biosight stockholders will hold 55 percent of the ownership in the combined company, while Ayala stockholders will retain the remaining 45 percent. The focus of the new combined company will be to advance a portfolio of oncology assets, with particular emphasis on two drugs: AL102 and Aspacytarabine (BST-236).

Ayala Pharmaceuticals and Biosight are merging to harness their assets and expertise in oncology, accelerating the development of promising drugs, including AL102 and Aspacytarabine (BST-236). The combined effort aims to bring these innovative treatments to the market swiftly, improving the outlook for those in need of effective therapies.

AL102 is an investigational small molecule gamma-secretase inhibitor (GSI) developed by Ayala Pharmaceuticals. It is designed to selectively inhibit Notch 1, 2, 3, and 4. The drug works by blocking the final cleavage step by the gamma-secretase, which is required for Notch activation. AL102 is currently being evaluated in the Phase 2/3 RINGSIDE clinical studies in patients with progressing desmoid tumours. Desmoid tumours are a rare type of soft tissue tumour.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024